Detection of minimal residual disease in multiple myeloma using cell-free DNA

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Lenka BEŠŠE, Roman HÁJEK a Sabina ŠEVČÍKOVÁ. Detection of minimal residual disease in multiple myeloma using cell-free DNA. In The Biomania Student Scientific Meeting 2015. 2015. ISBN 978-80-210-7933-5.

Základní údaje

• Originální název: Detection of minimal residual disease in multiple myeloma using cell-free DNA
• Autoři: KUBACZKOVÁ, Veronika (203 Česká republika, domácí), Lenka SEDLAŘÍKOVÁ (203 Česká republika, domácí), Lenka BEŠŠE (203 Česká republika, domácí), Roman HÁJEK (203 Česká republika, domácí) a Sabina ŠEVČÍKOVÁ (203 Česká republika, garant, domácí).
• Vydání: The Biomania Student Scientific Meeting 2015, 2015.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Konferenční abstrakt
• Obor: 30200 3.2 Clinical medicine
• Stát vydavatele: Česká republika
• Utajení: není předmětem státního či obchodního tajemství
• Kód RIV: RIV/00216224:14110/15:00091269
• Organizační jednotka: Lékařská fakulta
• ISBN: 978-80-210-7933-5
• Klíčová slova anglicky: cell-free DNA; multiple myeloma; minimal residual disease
• Štítky: EL OK

Anotace

Cell-free DNA (cf-DNA) detected in serum of peripheral blood has recently become a suitable minimally invasive diagnostic tool for diagnosis and monitoring of a variety of malignant diseases including multiple myeloma (MM). MM is a malignant disease of plasma cells (PB). Despite significant advances in treatment, majority of patients relapse. Monitoring of minimal residual disease (MRD) allows identification of patients who are at risk of relapse. The golden standard for detection of MRD in MM is flow cytometric analysis of bone marrow cells (BM) and PCR-based methodology of a tumor marker - specific rearrangement of the immunoglobulin heavy chain (IGH). The aim of our study was to assess MRD in MM patients by detecting serum cf-DNA carrying a tumor-specific marker that was analyzed at the time of diagnosis of PB in BM. Using real-time PCR and droplet-digital PCR, we analyzed 61 serum samples obtained at the time of diagnosis and at various time point of treatment. Our results indicate the potential use of detection of cf-DNA in MM patients for disease monitoring. However, potential benefits and predictive value of cf-DNA need to be verified on a larger cohort of patients.